Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xenadrine EFX is a multi-ingredient dietary supplement marketed for weight loss and energy enhancement. It was developed as an "ephedra-free" (EFX) alternative following the FDA ban on ephedrine alkaloids in dietary supplements. The formulation typically contains a blend of stimulants, including caffeine, guarana extract, and bitter orange (*Citrus aurantium*) extract standardized for synephrine. Synephrine acts as a sympathomimetic agent, primarily targeting alpha-adrenergic receptors, which can increase systemic vascular resistance and blood pressure. Clinical studies and case reports have associated its use with cardiovascular stimulant effects, including hypertensive urgency and increased heart rate, particularly when combined with caffeine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xenadrine EFX.